Literature DB >> 8260647

Interleukin-2 receptor heterotrimer complex and intracellular signaling.

M Nakamura1, H Asao, T Takeshita, K Sugamura.   

Abstract

Identification of a third component of the IL-2 receptor complex, gamma-chain, has established that the high-affinity complex consists of at least three distinct subunits, alpha-, beta- and gamma-chains. The alpha-chain specifies the low-affinity IL-2 binding. The beta- or gamma-chains alone do not show any appreciable IL-2 binding activity, however simultaneous existence of both chains generates a functional receptor complex that is suggested to associate with a non-receptor type protein tyrosine kinase that may deliver IL-2-induced signals further downstream. Mutation studies have revealed that discrete cytoplasmic regions of the beta- and gamma-chains transduce at least two independent signaling pathways.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8260647     DOI: 10.1006/smim.1993.1037

Source DB:  PubMed          Journal:  Semin Immunol        ISSN: 1044-5323            Impact factor:   11.130


  9 in total

1.  Interleukin-15 plays an essential role in the pathogenesis of autoimmune diabetes in the NOD mouse.

Authors:  D Bobbala; X-L Chen; C Leblanc; M Mayhue; J Stankova; T Tanaka; Y-G Chen; S Ilangumaran; S Ramanathan
Journal:  Diabetologia       Date:  2012-08-14       Impact factor: 10.122

2.  Fine epitope specificity of antibodies against interleukin-2 explains their paradoxical immunomodulatory effects.

Authors:  Gertrudis Rojas; Yanelys Cabrera Infante; Amaury Pupo; Tania Carmenate
Journal:  MAbs       Date:  2013-11-19       Impact factor: 5.857

3.  Genetic regulation of long-term nonprogression in E-55+ murine leukemia virus infection in mice.

Authors:  V Panoutsakopoulou; K Hunter; T G Sieck; E P Blankenhorn; K J Blank
Journal:  J Virol       Date:  1999-11       Impact factor: 5.103

4.  Chromosome mapping of Rfv3, a host resistance gene to Friend murine retrovirus.

Authors:  K J Hasenkrug; A Valenzuela; V A Letts; J Nishio; B Chesebro; W N Frankel
Journal:  J Virol       Date:  1995-04       Impact factor: 5.103

5.  CD4+ T cell-derived IL-2 signals during early priming advances primary CD8+ T cell responses.

Authors:  Yo-Ping Lai; Chia-Ching Lin; Wan-Jung Liao; Chih-Yung Tang; Shu-Ching Chen
Journal:  PLoS One       Date:  2009-11-10       Impact factor: 3.240

6.  NetPath: a public resource of curated signal transduction pathways.

Authors:  Kumaran Kandasamy; S Sujatha Mohan; Rajesh Raju; Shivakumar Keerthikumar; Ghantasala S Sameer Kumar; Abhilash K Venugopal; Deepthi Telikicherla; J Daniel Navarro; Suresh Mathivanan; Christian Pecquet; Sashi Kanth Gollapudi; Sudhir Gopal Tattikota; Shyam Mohan; Hariprasad Padhukasahasram; Yashwanth Subbannayya; Renu Goel; Harrys K C Jacob; Jun Zhong; Raja Sekhar; Vishalakshi Nanjappa; Lavanya Balakrishnan; Roopashree Subbaiah; Y L Ramachandra; B Abdul Rahiman; T S Keshava Prasad; Jian-Xin Lin; Jon C D Houtman; Stephen Desiderio; Jean-Christophe Renauld; Stefan N Constantinescu; Osamu Ohara; Toshio Hirano; Masato Kubo; Sujay Singh; Purvesh Khatri; Sorin Draghici; Gary D Bader; Chris Sander; Warren J Leonard; Akhilesh Pandey
Journal:  Genome Biol       Date:  2010-01-12       Impact factor: 13.583

Review 7.  Structural biology of shared cytokine receptors.

Authors:  Xinquan Wang; Patrick Lupardus; Sherry L Laporte; K Christopher Garcia
Journal:  Annu Rev Immunol       Date:  2009       Impact factor: 28.527

8.  Clonal and functional analysis for the augmentation of tumour-infiltrating lymphocytes by interleukin 4.

Authors:  T Tsunoda; H Tanimura; H Yamaue; M Iwahashi; M Tani; K Noguchi; T Hotta; S Mizobata; K Arii
Journal:  Br J Cancer       Date:  1996-10       Impact factor: 7.640

9.  Interleukin-1 alpha increases the preferential cytotoxicity of an interleukin-2-diphtheria toxin fusion protein against neoplastic lymphocytes from patients with the Sezary syndrome compared to normal lymphocytes.

Authors:  D Salard; T M Kuzel; E Samuelson; S Rosen; O Bakouche
Journal:  J Clin Immunol       Date:  1998-05       Impact factor: 8.542

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.